Polymonoclonal (Not Polyclonal) Antibodies Derived from Convalescent Human B Cell Hybridomas Might Be a Better Therapeutic Option than Single Target Monoclonal Antibodies | Zendy

Feroza Begum | Zendy; Upasana Ray | Zendy

Open Access

Polymonoclonal (Not Polyclonal) Antibodies Derived from Convalescent Human B Cell Hybridomas Might Be a Better Therapeutic Option than Single Target Monoclonal Antibodies

Author(s) -

Feroza Begum,

Upasana Ray

Publication year - 2020

Publication title -

acs pharmacology and translational science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.271

H-Index - 10

ISSN - 2575-9108

DOI - 10.1021/acsptsci.0c00084

Subject(s) - monoclonal antibody , polyclonal antibodies , antibody , virology , monoclonal , b cell , immunology , cell , medicine , biology , genetics

Both human B cell hybridoma technology and convalescent plasma therapy are promising immunological tools for therapeutic interventions. Here we propose using antibody producing B cells from convalescent SARS-CoV2 patients for developing human B cell hybridomas, and a combination of monoclonal antibodies against multiple immunogenic targets of SARS-CoV-2 spike protein might deliver an antibody cocktail for long-lasting therapeutic targeting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research